Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Immunotherapy. 2012 Dec;4(12):1795-8. doi: 10.2217/imt.12.126.
Evaluation of: Chiba S, Baghdadi M, Akiba H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832-842 (2012). The identification of TIM-3 expression on tumor-associated dendritic cells (TADCs) provides insight into another aspect of tumor-mediated immunosuppression. The role of TIM-3 has been well characterized on tumor-infiltrating T cells; however, its role on TADCs was not previously known. The current paper demonstrated that TIM-3 was predominantly expressed by TADCs and its interaction with the nuclear protein HMGB1 suppressed nucleic acid-mediated activation of an effective antitumor immune response. The authors were able to show that TIM-3 interaction with HMGB1 prevented the localization of nucleic acids into endosomal vesicles. Furthermore, chemotherapy was found to be more effective in anti-TIM-3 monoclonal antibody-treated mice or mice depleted of all DCs, which indicated that a significant role is played by TADCs in inhibiting tumor regression. Taken together, these findings identify TIM-3 as a potential target for inducing antitumor immunity in conjunction with DNA vaccines and/or immunogenic chemotherapy in clinical settings.
千葉 S、Baghdadi M、赤﨑 H 等人。肿瘤浸润树突状细胞(TADCs)通过 TIM-3 受体与警报素 HMGB1 的相互作用抑制核酸介导的固有免疫反应。Nat. Immunol. 13, 832-842 (2012)。在肿瘤相关树突状细胞(TADCs)上表达 TIM-3 的鉴定为肿瘤介导的免疫抑制提供了另一个方面的见解。TIM-3 在上的作用肿瘤浸润 T 细胞已有很好的描述;然而,其在 TADCs 上的作用以前并不清楚。目前的论文表明,TIM-3 主要由 TADCs 表达,其与核蛋白 HMGB1 的相互作用抑制了核酸介导的有效抗肿瘤免疫反应的激活。作者能够表明 TIM-3 与 HMGB1 的相互作用阻止了核酸进入内体小泡的定位。此外,发现化疗在抗 TIM-3 单克隆抗体治疗的小鼠或耗尽所有树突状细胞的小鼠中更有效,这表明 TADCs 在抑制肿瘤消退方面发挥了重要作用。总之,这些发现确定 TIM-3 作为与 DNA 疫苗和/或免疫原性化疗联合诱导抗肿瘤免疫的潜在靶点的临床环境。